JP2008525003A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008525003A5 JP2008525003A5 JP2007547535A JP2007547535A JP2008525003A5 JP 2008525003 A5 JP2008525003 A5 JP 2008525003A5 JP 2007547535 A JP2007547535 A JP 2007547535A JP 2007547535 A JP2007547535 A JP 2007547535A JP 2008525003 A5 JP2008525003 A5 JP 2008525003A5
- Authority
- JP
- Japan
- Prior art keywords
- influenza
- polymerase
- nucleic acid
- cell
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims description 64
- 108090000623 proteins and genes Proteins 0.000 claims description 44
- 241000700605 Viruses Species 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 39
- 108020004707 nucleic acids Proteins 0.000 claims description 36
- 102000039446 nucleic acids Human genes 0.000 claims description 36
- 150000007523 nucleic acids Chemical class 0.000 claims description 36
- 241000712461 unidentified influenza virus Species 0.000 claims description 32
- 239000013612 plasmid Substances 0.000 claims description 31
- 238000004519 manufacturing process Methods 0.000 claims description 24
- 206010022000 influenza Diseases 0.000 claims description 19
- 239000002245 particle Substances 0.000 claims description 14
- 238000001890 transfection Methods 0.000 claims description 12
- 208000037797 influenza A Diseases 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical group O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 9
- 241001515965 unidentified phage Species 0.000 claims description 9
- 229960005486 vaccine Drugs 0.000 claims description 9
- 102000011931 Nucleoproteins Human genes 0.000 claims description 7
- 108010061100 Nucleoproteins Proteins 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 241000894007 species Species 0.000 claims description 6
- 241000288906 Primates Species 0.000 claims description 5
- 230000000295 complement effect Effects 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 230000001900 immune effect Effects 0.000 claims description 4
- 230000003362 replicative effect Effects 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 108010077850 Nuclear Localization Signals Proteins 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 230000010076 replication Effects 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 2
- 230000008520 organization Effects 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims 4
- 241000701867 Enterobacteria phage T7 Species 0.000 claims 2
- 108091034135 Vault RNA Proteins 0.000 claims 1
- 210000004102 animal cell Anatomy 0.000 claims 1
- 101710154606 Hemagglutinin Proteins 0.000 description 18
- 241001500351 Influenzavirus A Species 0.000 description 18
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 18
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 18
- 101710176177 Protein A56 Proteins 0.000 description 18
- 239000000185 hemagglutinin Substances 0.000 description 18
- 230000002068 genetic effect Effects 0.000 description 14
- 108020000999 Viral RNA Proteins 0.000 description 12
- 239000013598 vector Substances 0.000 description 12
- 230000002457 bidirectional effect Effects 0.000 description 11
- 241000712431 Influenza A virus Species 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 102000005348 Neuraminidase Human genes 0.000 description 9
- 108010006232 Neuraminidase Proteins 0.000 description 9
- 239000002299 complementary DNA Substances 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 7
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 7
- 108010089610 Nuclear Proteins Proteins 0.000 description 7
- 239000005090 green fluorescent protein Substances 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- 101710144128 Non-structural protein 2 Proteins 0.000 description 6
- 102000007999 Nuclear Proteins Human genes 0.000 description 6
- 101710199667 Nuclear export protein Proteins 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 241000271566 Aves Species 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 108091092724 Noncoding DNA Proteins 0.000 description 5
- 230000000692 anti-sense effect Effects 0.000 description 5
- 238000002941 microtiter virus yield reduction assay Methods 0.000 description 5
- 241000282465 Canis Species 0.000 description 4
- 108060003393 Granulin Proteins 0.000 description 4
- 241000711798 Rabies lyssavirus Species 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 238000010899 nucleation Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 208000037798 influenza B Diseases 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 108020004418 ribosomal RNA Proteins 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 230000029812 viral genome replication Effects 0.000 description 3
- 101150002210 34 gene Proteins 0.000 description 2
- 101150044182 8 gene Proteins 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 101000686777 Escherichia phage T7 T7 RNA polymerase Proteins 0.000 description 2
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 241000713297 Influenza C virus Species 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 108700009124 Transcription Initiation Site Proteins 0.000 description 2
- 108700005077 Viral Genes Proteins 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 208000037799 influenza C Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 241000856131 recombinant Influenza A viruses Species 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000711950 Filoviridae Species 0.000 description 1
- 241000342334 Human metapneumovirus Species 0.000 description 1
- 241000712003 Human respirovirus 3 Species 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000712464 Orthomyxoviridae Species 0.000 description 1
- 108091036407 Polyadenylation Proteins 0.000 description 1
- 108010013845 RNA Polymerase I Proteins 0.000 description 1
- 102000017143 RNA Polymerase I Human genes 0.000 description 1
- 108010065868 RNA polymerase SP6 Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000711931 Rhabdoviridae Species 0.000 description 1
- 102000004389 Ribonucleoproteins Human genes 0.000 description 1
- 108010081734 Ribonucleoproteins Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241001468001 Salmonella virus SP6 Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000002358 autolytic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000005257 nucleotidylation Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04078527 | 2004-12-24 | ||
| EP04078527.1 | 2004-12-24 | ||
| US64100305P | 2005-01-04 | 2005-01-04 | |
| US60/641,003 | 2005-01-04 | ||
| PCT/EP2005/057092 WO2006067211A1 (en) | 2004-12-24 | 2005-12-22 | Rescue of influenza virus |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012065345A Division JP5702321B2 (ja) | 2004-12-24 | 2012-03-22 | インフルエンザウイルスの救済（ｒｅｓｃｕｅ） |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008525003A JP2008525003A (ja) | 2008-07-17 |
| JP2008525003A5 true JP2008525003A5 (enExample) | 2012-05-31 |
| JP5620048B2 JP5620048B2 (ja) | 2014-11-05 |
Family
ID=34928779
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007547535A Expired - Fee Related JP5620048B2 (ja) | 2004-12-24 | 2005-12-22 | インフルエンザウイルスの救済（ｒｅｓｃｕｅ） |
| JP2012065345A Expired - Fee Related JP5702321B2 (ja) | 2004-12-24 | 2012-03-22 | インフルエンザウイルスの救済（ｒｅｓｃｕｅ） |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012065345A Expired - Fee Related JP5702321B2 (ja) | 2004-12-24 | 2012-03-22 | インフルエンザウイルスの救済（ｒｅｓｃｕｅ） |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US7959930B2 (enExample) |
| EP (2) | EP1831357B1 (enExample) |
| JP (2) | JP5620048B2 (enExample) |
| KR (1) | KR101272487B1 (enExample) |
| CN (1) | CN101379183B (enExample) |
| AU (1) | AU2005318087B2 (enExample) |
| BR (1) | BRPI0518568A2 (enExample) |
| CA (1) | CA2592439C (enExample) |
| DK (1) | DK1831357T3 (enExample) |
| ES (1) | ES2395813T3 (enExample) |
| IL (1) | IL183888A (enExample) |
| MX (1) | MX2007007889A (enExample) |
| NO (1) | NO20073737L (enExample) |
| NZ (1) | NZ556061A (enExample) |
| PT (1) | PT1831357E (enExample) |
| RU (2) | RU2435855C2 (enExample) |
| TW (2) | TWI495724B (enExample) |
| WO (1) | WO2006067211A1 (enExample) |
| ZA (1) | ZA200705145B (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA93981C2 (ru) | 2001-01-19 | 2011-03-25 | Вироновативе Б.B. | Вирус, который вызывает заболевание дыхательных путей у чувствительных k этому млекопитающих |
| CA2477235A1 (en) | 2002-02-21 | 2003-09-04 | Medimmune Vaccines, Inc. | Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus |
| AU2005318087B2 (en) * | 2004-12-24 | 2011-04-21 | Abbott Biologicals B.V. | Rescue of influenza virus |
| CA2613284A1 (en) * | 2005-06-21 | 2007-01-04 | Medimmune Vaccines, Inc. | Methods and compositions for expressing negative-sense viral rna in canine cells |
| US7790434B2 (en) | 2005-06-21 | 2010-09-07 | Medimmune, Llc | Methods and compositions for expressing negative-sense viral RNA in canine cells |
| EA014028B1 (ru) | 2005-11-04 | 2010-08-30 | Новартис Вэксинс Энд Диагностикс Срл | Эмульсии, содержащие свободное поверхностно-активное вещество в водной фазе в качестве адъюванта сплит вакцин против гриппа |
| WO2007052058A1 (en) | 2005-11-04 | 2007-05-10 | Novartis Vaccines And Diagnostics Srl | Influenza vaccines including combinations of particulate adjuvants and immunopotentiators |
| NZ592713A (en) | 2005-11-04 | 2012-12-21 | Novartis Vaccines & Diagnostic | Adjuvanted influenza vaccines including a cytokine-inducing agents other than an agonist of Toll-Like Receptor 9 |
| AU2006310163B2 (en) | 2005-11-04 | 2011-09-15 | Seqirus UK Limited | Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant |
| HUE051122T2 (hu) | 2005-11-04 | 2021-03-01 | Seqirus Uk Ltd | Sejttenyészetben növesztett influenzavírusból elõállított nemvirion anti-géneket tartalmazó adjuvált vakcinák |
| HUE049580T2 (hu) | 2006-01-27 | 2020-09-28 | Seqirus Uk Ltd | Hemagglutinint és mátrixfehérjéket tartalmazó, influenza elleni oltóanyagok |
| CN101448523A (zh) | 2006-03-24 | 2009-06-03 | 诺华疫苗和诊断有限两合公司 | 无需冷藏储存流感疫苗 |
| WO2007126810A2 (en) | 2006-03-31 | 2007-11-08 | Warf - Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses for vaccines |
| US7682619B2 (en) | 2006-04-06 | 2010-03-23 | Cornell Research Foundation, Inc. | Canine influenza virus |
| GB0614460D0 (en) | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
| EP4585610A3 (en) | 2006-09-11 | 2025-09-24 | Seqirus UK Limited | Making influenza virus vaccines without using eggs |
| PL2121011T3 (pl) | 2006-12-06 | 2014-10-31 | Novartis Ag | Szczepionki zawierające antygeny czterech szczepów wirusa grypy |
| WO2008156778A2 (en) | 2007-06-18 | 2008-12-24 | Tokiko Watanabe | Influenza m2 protein mutant viruses as live influenza attenuated vaccines |
| CN101784283A (zh) | 2007-06-27 | 2010-07-21 | 诺华有限公司 | 低添加流感疫苗 |
| GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
| EA201071086A1 (ru) | 2008-03-18 | 2011-04-29 | Новартис Аг | Усовершенствованный способ получения вакцинных антигенов вируса гриппа |
| US20120093859A1 (en) | 2009-02-10 | 2012-04-19 | Novartis Ag | Influenza vaccine regimens for pandemic-associated strains |
| EP3173097A3 (en) | 2009-02-10 | 2017-07-12 | Seqirus UK Limited | Influenza vaccines with reduced amounts of squalene |
| EP2396031A1 (en) | 2009-02-10 | 2011-12-21 | Novartis AG | Influenza vaccines with increased amounts of h3 antigen |
| CN102548577A (zh) | 2009-04-27 | 2012-07-04 | 诺华有限公司 | 用于抵抗流感的佐剂疫苗 |
| AU2010277310B2 (en) | 2009-07-31 | 2015-01-15 | Seqirus UK Limited | Reverse genetics systems |
| WO2011056591A1 (en) | 2009-10-26 | 2011-05-12 | Warf - Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses with enhanced replication in vero cells |
| US10130697B2 (en) | 2010-03-23 | 2018-11-20 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
| CN103237890A (zh) * | 2010-06-02 | 2013-08-07 | 巴克斯特保健股份有限公司 | 用于产生rna 病毒的方法和辅助病毒 |
| FR2962739B1 (fr) * | 2010-07-13 | 2014-01-31 | Univ Claude Bernard Lyon | Souches virales modifiees et procede pour ameliorer la production de semences vaccinales de virus influenza |
| JP2014527799A (ja) | 2011-08-26 | 2014-10-23 | ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション | 変異型ｐｂ２遺伝子セグメントを有する弱毒化生ワクチンとしてのインフルエンザウイルス |
| WO2013057715A1 (en) | 2011-10-20 | 2013-04-25 | Novartis Ag | Adjuvanted influenza b virus vaccines for pediatric priming |
| GB201218195D0 (en) | 2012-10-10 | 2012-11-21 | Istituto Zooprofilattico Sperimentale Delle Venezie | Composition |
| WO2014145287A2 (en) * | 2013-03-15 | 2014-09-18 | University Of Maryland | Swine influenza viruses and constructs and uses thereof |
| WO2015009743A1 (en) | 2013-07-15 | 2015-01-22 | Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses with enhanced replication in mdck or vero cells or eggs |
| US10053671B2 (en) | 2014-06-20 | 2018-08-21 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
| US10633422B2 (en) | 2015-06-01 | 2020-04-28 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA |
| CA2986701A1 (en) * | 2015-06-09 | 2016-12-15 | Sanofi Pasteur, Inc. | Methods of optimizing nucleotide sequences encoding engineered influenza proteins |
| BR112017028011A2 (pt) | 2015-06-26 | 2018-08-28 | Seqirus Uk Ltd | vacinas de gripe correspondentes antigenicamente |
| US9890363B2 (en) | 2015-07-06 | 2018-02-13 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication for vaccine development |
| CN108027371B (zh) | 2015-07-07 | 2020-08-18 | 思齐乐 | 流感效力试验 |
| WO2017143236A1 (en) | 2016-02-19 | 2017-08-24 | Yoshihiro Kawaoka | Improved influenza b virus replication for vaccine development |
| US11197926B2 (en) | 2017-10-25 | 2021-12-14 | Wisconsin Alumni Research Foundation (Warf) | Recombinant influenza viruses with stabilized HA for replication in eggs |
| JP7783047B2 (ja) | 2018-08-07 | 2025-12-09 | ウィスコンシン アルムニ リサーチ ファンデイション | 組換えの生物学的に封じ込められたフィロウイルスワクチン |
| JP7655849B2 (ja) | 2018-08-20 | 2025-04-02 | ウィスコンシン アルムニ リサーチ ファンデイション | ヘマグルチニン（ｈａ）タンパク質内の非ドミナントエピトープに対する免疫応答を誘起するためのベクター |
| JP2022527235A (ja) | 2019-01-23 | 2022-06-01 | 義裕 河岡 | インフルエンザウイルスにおける付加的遺伝子に遺伝的安定性を付与する突然変異 |
| EP3921413A1 (en) | 2019-02-08 | 2021-12-15 | Wisconsin Alumni Research Foundation (WARF) | Humanized cell line |
| US11390649B2 (en) | 2019-05-01 | 2022-07-19 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication for vaccine development |
| US11807872B2 (en) | 2019-08-27 | 2023-11-07 | Wisconsin Alumni Research Foundation (Warf) | Recombinant influenza viruses with stabilized HA for replication in eggs |
| JP2023511444A (ja) | 2020-01-24 | 2023-03-17 | ウィスコンシン アルムニ リサーチ ファンデイション | 安定化されたｎａを有する組換えインフルエンザウイルス |
| WO2021195410A1 (en) | 2020-03-25 | 2021-09-30 | Wisconsin Alumni Research Foundation (Warf) | Recombinant multivalent influenza viruses |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6001634A (en) * | 1989-08-28 | 1999-12-14 | Palese; Peter | Recombinant negative strand RNA viruses |
| US5854037A (en) * | 1989-08-28 | 1998-12-29 | The Mount Sinai School Of Medicine Of The City University Of New York | Recombinant negative strand RNA virus expression systems and vaccines |
| US5166057A (en) * | 1989-08-28 | 1992-11-24 | The Mount Sinai School Of Medicine Of The City University Of New York | Recombinant negative strand rna virus expression-systems |
| US6887699B1 (en) * | 1990-05-22 | 2005-05-03 | Medimmune Vaccines, Inc. | Recombinant negative strand RNA virus expression systems and vaccines |
| US6544785B1 (en) * | 1998-09-14 | 2003-04-08 | Mount Sinai School Of Medicine Of New York University | Helper-free rescue of recombinant negative strand RNA viruses |
| EP2345716B1 (en) | 1999-04-06 | 2015-01-14 | Wisconsin Alumni Research Foundation | Recombinant influenza viruses for vaccines and gene therapy |
| US8715940B2 (en) * | 1999-04-06 | 2014-05-06 | Wisconsin Alumni Research Foundation | Method of making recombinant influenza virus |
| DE122007000070I1 (de) | 1999-07-14 | 2008-01-31 | Sinai School Medicine | In Vitro-rekonstitution von segmentierten Negativstrang-Rna-Viren |
| IL147857A0 (en) * | 1999-08-02 | 2002-08-14 | American Cyanamid Co | RESCUE OF MUMPS VIRUS FROM cDNA |
| US6764685B1 (en) * | 2000-03-21 | 2004-07-20 | Medimmune Vaccines, Inc. | Recombinant parainfluenza virus expression systems and vaccines |
| DE60137345D1 (de) | 2000-04-28 | 2009-02-26 | St Jude Childrens Res Hospital | Dna-transfektionssystem zur erzeugung von infektiösen negativsträngigen rna virus |
| EP1292614A2 (en) * | 2000-06-23 | 2003-03-19 | American Cyanamid Company | Nucleotide sequence of influenza a/udorn/72 (h3n2) genome |
| CA2477235A1 (en) * | 2002-02-21 | 2003-09-04 | Medimmune Vaccines, Inc. | Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus |
| CN103540613A (zh) * | 2002-04-26 | 2014-01-29 | 米迪缪尼有限公司 | 制备流感病毒的多质粒系统 |
| US7037707B2 (en) * | 2003-09-04 | 2006-05-02 | St. Jude Children's Research Hospital | Method for generating influenza viruses and vaccines |
| AU2005318087B2 (en) * | 2004-12-24 | 2011-04-21 | Abbott Biologicals B.V. | Rescue of influenza virus |
-
2005
- 2005-12-22 AU AU2005318087A patent/AU2005318087B2/en not_active Ceased
- 2005-12-22 CA CA2592439A patent/CA2592439C/en not_active Expired - Fee Related
- 2005-12-22 EP EP05825287A patent/EP1831357B1/en not_active Expired - Lifetime
- 2005-12-22 ES ES05825287T patent/ES2395813T3/es not_active Expired - Lifetime
- 2005-12-22 JP JP2007547535A patent/JP5620048B2/ja not_active Expired - Fee Related
- 2005-12-22 KR KR1020077017093A patent/KR101272487B1/ko not_active Expired - Fee Related
- 2005-12-22 WO PCT/EP2005/057092 patent/WO2006067211A1/en not_active Ceased
- 2005-12-22 DK DK05825287.5T patent/DK1831357T3/da active
- 2005-12-22 US US11/722,769 patent/US7959930B2/en not_active Expired - Fee Related
- 2005-12-22 PT PT58252875T patent/PT1831357E/pt unknown
- 2005-12-22 EP EP10182258A patent/EP2295542B1/en not_active Expired - Lifetime
- 2005-12-22 RU RU2007128336/10A patent/RU2435855C2/ru not_active IP Right Cessation
- 2005-12-22 CN CN2005800447512A patent/CN101379183B/zh not_active Expired - Fee Related
- 2005-12-22 BR BRPI0518568-8A patent/BRPI0518568A2/pt not_active IP Right Cessation
- 2005-12-22 NZ NZ556061A patent/NZ556061A/en not_active IP Right Cessation
- 2005-12-22 MX MX2007007889A patent/MX2007007889A/es active IP Right Grant
- 2005-12-23 TW TW101113590A patent/TWI495724B/zh not_active IP Right Cessation
- 2005-12-23 TW TW094146438A patent/TWI402344B/zh not_active IP Right Cessation
-
2007
- 2007-06-13 IL IL183888A patent/IL183888A/en not_active IP Right Cessation
- 2007-06-21 ZA ZA200705145A patent/ZA200705145B/xx unknown
- 2007-07-18 NO NO20073737A patent/NO20073737L/no not_active Application Discontinuation
-
2011
- 2011-04-15 US US13/088,120 patent/US20120156241A1/en not_active Abandoned
- 2011-05-31 RU RU2011122117/10A patent/RU2011122117A/ru not_active Application Discontinuation
-
2012
- 2012-03-22 JP JP2012065345A patent/JP5702321B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008525003A5 (enExample) | ||
| EP1831357B1 (en) | Rescue of influenza virus | |
| Neumann et al. | Reverse genetics of influenza virus | |
| Inoue et al. | An improved method for recovering rabies virus from cloned cDNA | |
| Neumann et al. | Reverse genetics systems for the generation of segmented negative-sense RNA viruses entirely from cloned cDNA | |
| CN101580849B (zh) | 用于产生感染性流感病毒的dna转染系统 | |
| US20090017444A1 (en) | Screening method for modulators of viral transcription or replication | |
| Neumann et al. | Generation of influenza A virus from cloned cDNAs—historical perspective and outlook for the new millenium | |
| IL151426A (en) | Compounds of 4,3 - Dihydro - H1 - Pyrimido [D - 4, 5] Pyrimidine - 2 - On-converted at position 1.5 and their use in the preparation of drugs for the treatment of diseases caused by 38P / CSBP kinase | |
| Neumann | Influenza reverse genetics—historical perspective | |
| AU2012317159B2 (en) | Two plasmid mammalian expression system | |
| Kawaoka | Biology of negative strand RNA viruses: the power of reverse genetics | |
| AU2011204881B2 (en) | Rescue of influenza virus | |
| Edenborough et al. | Reverse genetics: Unlocking the secrets of negative sense RNA viral pathogens | |
| Minskaia et al. | Reverse Genetics of the Negative-Sense Influenza A Virus: Aspects and Applications | |
| HK1153237A (en) | Rescue of influenza virus | |
| HK1125674B (zh) | 流感病毒的拯救 | |
| NZ536260A (en) | Development of a multi-plasmid pol I - pol II based system for the generation of infectious influenza RNA viruses from cloned DNA |